Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 20 February 2025, 12:29 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives

TOKYO, Feb 20, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for “Human CapitalLeaders 2024” and “Human Capital Management Gold Quality” in the “Human Capital Survey 2024” jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise. This is the second consecutive year that Eisai has been selected.

In the “Human Capital Survey 2024” (conducted between August and December 2024), 17 highly rated companies were selected for “Human Capital Management Gold Quality”, and 10 companies that were recognized by experts as having made particularly outstanding efforts were selected as “Human Capital Leaders 2024” out of approximately 400 participating companies and organizations. Eisai was highly evaluated for its various initiatives implementing human capital management aligned with its Articles of Incorporation based on detailed analysis of its current situation and future aspirations, proactive information disclosure with unique performance indicators such as employee impact accounting, as well as its measures for facilitating smooth internal communication.

To increase the value of our employees, Eisai made a partial amendment to the Articles of Incorporation at an Ordinary GeneralMeeting of Shareholders in 2022, clearly stating that it will strive to “ensure stable employment”, “respect human rights and diversity”, “provide full opportunities for growth to support self- fulfillment”, and “create an employee-friendly environment”. Eisai has also reinforced its human resource initiatives, including the formulation of an “Integrated Human Resource Strategy”, with the pillars of “Wellbeing including health of employees”, “Diverse work style”, “Development and growth of employees”, and “Growth ofthe organization and businesses”, as well as introducing a compensation system based on employee roles since 2023, along with a personnel assessment system putting high value on employee actions with the aim of encouraging employees to growautonomously and motivate them to serve in higher positions. Eisai promotes proactive information disclosure regarding its initiatives on human capital management in its “Value Creation Report” and its corporate website’s “Sustainability” section, as wellas its “Human Capital Report” which has been published since 2023 summarizing its human capital initiatives and KPI linked to its human resource strategies.

Eisai is seeking to provide impact to not only our shareholders, but various stakeholders including our customers and local communities by delivering new value to patients and the people in the daily living domain through the activities of our employees who are the only stakeholders who can directly contribute to our corporate concept, human health care.

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: